45
Participants
Start Date
April 30, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
CRYONOVE (EC14_4osc)
The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
CRYONOVE (EC+05_1osc)
The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
CRYONOVE (EC+05_2osc)
The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Lead Sponsor
Cryonove Pharma
INDUSTRY